PE20200664A1 - Compuestos espirociclicos y sus metodos de preparacion y uso - Google Patents
Compuestos espirociclicos y sus metodos de preparacion y usoInfo
- Publication number
- PE20200664A1 PE20200664A1 PE2020000296A PE2020000296A PE20200664A1 PE 20200664 A1 PE20200664 A1 PE 20200664A1 PE 2020000296 A PE2020000296 A PE 2020000296A PE 2020000296 A PE2020000296 A PE 2020000296A PE 20200664 A1 PE20200664 A1 PE 20200664A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heteroaryl ring
- formula
- compounds
- halogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a compuestos derivados de hexafluoropropan-diazaespiro[4.5]decan-carboxilato y hexafluoropropan-piperidin-carboxilato de formulas (III), (I), (II) y (IV), y a sus solvatos, hidratos, tautomeros, esteroisomeros, N-oxidos y sales farmaceutica aceptables, donde: i) En el compuesto de formula (III), X es -CH2- o -C(O)-; Y es un enlace, alquilo C1-C6, haloalquilo C1-C6 o cicloalquilo C3-C8; R1 y R2 son H o alquilo C1-C6; R3 es un anillo heteroarilo de 5 a 6 miembros o un anillo heteroarilo biciclico de 9 a 10 miembros opcionalmente sustituidos por 1 a 3 R4, donde R4 es alquilo C1-C6, halogeno, entre otros; n es 0 o 1 y m es 1 o 2, donde cuando n es 0, m es 2 y cuando n es 1, m es 1; ii) En el compuesto de formula (I), X es -CH2- o -C(O)-; R1 y R2 son alquilo C1-C6; R3 es un anillo heteroarilo de 5 a 6 miembros o un anillo heteroarilo biciclico de 9 a 10 miembros opcionalmente sustituidos por 1 a 3 R4, donde R4 es alquilo C1-C6, halogeno, entre otros; n es 0 o 1 y m es 1 o 2, donde cuando n es 0, m es 2 y cuando n es 1, m es 1; iii) En el compuesto de formula (II), Y es -CH2 o -C(O)-; Z es cicloalquilo C3-C6; R3 es un anillo heteroarilo de 5 a 6 miembros o un anillo heteroarilo biciclico de 9 a 10 miembros opcionalmente sustituidos por 1 a 3 R4, donde R4 es alquilo C1-C6, halogeno, entre otros; R11 es H, alquilo C1-C6 o -alquilo C1-C6-O-alquilo C1-C6; R12 es alquilo C1-C6, R13 es H o alquilo C1-C6 y v es 0 o 1; iv) En el compuesto de formula (IV), X es un enlace, -C(O)- o -S(O)2-; R1 es alquilo C1-C6, haloalquilo C1-C6, entre otros, opcionalmente sustituidos por 1 a 3 R2, donde R2 es halogeno, alquilo C1-C6 o haloalquilo C1-C6; y R3 es H, alquilo C1-C6, entre otros. Son compuestos preferidos los compuestos de formula a), b), c), d), entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son moduladores de MAGL, siendo utiles en el tratamiento de dolor neuropatico, dolor inflamatorio, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551721P | 2017-08-29 | 2017-08-29 | |
| PCT/US2018/048372 WO2019046318A1 (en) | 2017-08-29 | 2018-08-28 | SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200664A1 true PE20200664A1 (es) | 2020-06-11 |
Family
ID=65527860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000296A PE20200664A1 (es) | 2017-08-29 | 2018-08-28 | Compuestos espirociclicos y sus metodos de preparacion y uso |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11142526B2 (es) |
| EP (1) | EP3675847B1 (es) |
| JP (1) | JP7257387B2 (es) |
| KR (1) | KR20200046061A (es) |
| CN (1) | CN111050765B (es) |
| AU (1) | AU2018323459A1 (es) |
| BR (1) | BR112020004101A2 (es) |
| CA (1) | CA3072923A1 (es) |
| CL (1) | CL2020000462A1 (es) |
| CO (1) | CO2020001724A2 (es) |
| CR (1) | CR20200089A (es) |
| DO (1) | DOP2020000039A (es) |
| EA (1) | EA202090312A1 (es) |
| EC (1) | ECSP20013337A (es) |
| ES (1) | ES2952332T3 (es) |
| GE (1) | GEP20217327B (es) |
| IL (1) | IL272580B (es) |
| JO (1) | JOP20200023A1 (es) |
| MA (1) | MA50041A (es) |
| MX (1) | MX2020002251A (es) |
| NI (1) | NI202000014A (es) |
| PE (1) | PE20200664A1 (es) |
| PH (1) | PH12020500372A1 (es) |
| SG (1) | SG11202001022TA (es) |
| UA (1) | UA126685C2 (es) |
| WO (1) | WO2019046318A1 (es) |
| ZA (1) | ZA202001208B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2800565T3 (pl) | 2012-01-06 | 2020-09-21 | Lundbeck La Jolla Research Center, Inc. | Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie |
| US10030020B2 (en) | 2016-05-12 | 2018-07-24 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2018326497A1 (en) | 2017-08-29 | 2020-02-20 | H. Lundbeck A/S. | Spirocycle compounds and methods of making and using same |
| BR112020004101A2 (pt) | 2017-08-29 | 2020-09-24 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| EP4204420B1 (en) * | 2020-08-26 | 2024-08-07 | F. Hoffmann-La Roche AG | Heterocyclic compounds useful as magl inhibitors |
| TW202229255A (zh) | 2020-11-13 | 2022-08-01 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0207952A (pt) * | 2001-03-07 | 2004-07-27 | Pfizer Prod Inc | Moduladores da atividade de receptores de quimiocina |
| JPWO2008023720A1 (ja) | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
| AU2009221860A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| WO2011040905A1 (en) | 2009-09-29 | 2011-04-07 | Polyone Corporation | Polyester articles having simulated metallic or pearlescent appearance |
| TR201910327T4 (tr) | 2009-10-23 | 2019-07-22 | Janssen Pharmaceutica Nv | Oreksin reseptör modülatörleri olarak di-ornatılmış oktahidropirrolo [3,4-c]pirroller. |
| EP2542083B1 (en) | 2010-03-04 | 2015-05-06 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| FR2960875B1 (fr) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| PL2800565T3 (pl) * | 2012-01-06 | 2020-09-21 | Lundbeck La Jolla Research Center, Inc. | Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie |
| LT2900669T (lt) | 2012-09-25 | 2019-11-11 | Hoffmann La Roche | Heksahidropirol[3,4-c]pirolo dariniai ir susiję junginai kaip autotaksino (atx) inhibitoriai ir kaip lizofosfatidinės rūgšties (lpa) gamybos inhibitoriai, skirti gydyti pvz., inkstų ligas |
| US9828379B2 (en) | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| US10093630B2 (en) * | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| JP2018513119A (ja) | 2015-03-18 | 2018-05-24 | アビデ セラピューティクス，インク． | ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法 |
| JP6832914B2 (ja) | 2015-07-31 | 2021-02-24 | ファイザー・インク | Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体 |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| MY194647A (en) | 2016-03-31 | 2022-12-09 | Takeda Pharmaceuticals Co | Heterocyclic compound |
| US10030020B2 (en) | 2016-05-12 | 2018-07-24 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| TN2019000148A1 (en) | 2016-11-16 | 2020-10-05 | Abide Therapeutics Inc | Pharmaceutical formulations |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| WO2018093953A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Crystalline forms of a magl inhibitor |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| BR112020004101A2 (pt) | 2017-08-29 | 2020-09-24 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| AU2018326497A1 (en) | 2017-08-29 | 2020-02-20 | H. Lundbeck A/S. | Spirocycle compounds and methods of making and using same |
-
2018
- 2018-08-28 BR BR112020004101-7A patent/BR112020004101A2/pt unknown
- 2018-08-28 EA EA202090312A patent/EA202090312A1/ru unknown
- 2018-08-28 IL IL272580A patent/IL272580B/en unknown
- 2018-08-28 WO PCT/US2018/048372 patent/WO2019046318A1/en unknown
- 2018-08-28 KR KR1020207008312A patent/KR20200046061A/ko not_active Application Discontinuation
- 2018-08-28 EP EP18850498.9A patent/EP3675847B1/en active Active
- 2018-08-28 CA CA3072923A patent/CA3072923A1/en active Pending
- 2018-08-28 JP JP2020512586A patent/JP7257387B2/ja active Active
- 2018-08-28 UA UAA202001526A patent/UA126685C2/uk unknown
- 2018-08-28 MA MA050041A patent/MA50041A/fr unknown
- 2018-08-28 US US16/642,717 patent/US11142526B2/en active Active
- 2018-08-28 SG SG11202001022TA patent/SG11202001022TA/en unknown
- 2018-08-28 MX MX2020002251A patent/MX2020002251A/es unknown
- 2018-08-28 CN CN201880056725.9A patent/CN111050765B/zh active Active
- 2018-08-28 CR CR20200089A patent/CR20200089A/es unknown
- 2018-08-28 ES ES18850498T patent/ES2952332T3/es active Active
- 2018-08-28 GE GEAP201815281A patent/GEP20217327B/en unknown
- 2018-08-28 PE PE2020000296A patent/PE20200664A1/es unknown
- 2018-08-28 JO JOP/2020/0023A patent/JOP20200023A1/ar unknown
- 2018-08-28 AU AU2018323459A patent/AU2018323459A1/en not_active Abandoned
-
2020
- 2020-02-14 CO CONC2020/0001724A patent/CO2020001724A2/es unknown
- 2020-02-21 DO DO2020000039A patent/DOP2020000039A/es unknown
- 2020-02-21 EC ECSENADI202013337A patent/ECSP20013337A/es unknown
- 2020-02-24 NI NI202000014A patent/NI202000014A/es unknown
- 2020-02-24 PH PH12020500372A patent/PH12020500372A1/en unknown
- 2020-02-25 CL CL2020000462A patent/CL2020000462A1/es unknown
- 2020-02-26 ZA ZA2020/01208A patent/ZA202001208B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200664A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| PE20200665A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
| AR049706A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| AR047744A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
| AR046781A1 (es) | Derivados de imidazoquinolinas. composiciones farmaceuticas. | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR076264A1 (es) | Triazolopiridinas sustituidas y analogos de estas | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| WO2008115098A3 (fr) | 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR037288A1 (es) | Compuestos derivados de sulfonamidas, procedimiento para la obtencion, composicion farmaceutica y uso para la elaboracion de un medicamento | |
| PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos | |
| AR047958A1 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| PE20161369A1 (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona | |
| AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 |